NEW YORK, April 24 -  Microbead maker Luminex on Tuesday reported revenues of $3.9 million in the first quarter of 2001, up from $1.4 million in the year-ago quarter and in-line with its recently reduced forecast.

Last week the company slashed its revenue expectations for the first quarter of 2001, citing its partners’ delays in commercializing bioassay kits based on its technology. The company had initially forecasted that its first-quarter revenues would total $4.2 million to $4.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.